Remote Ischemic Post-Conditioning (RIC) Mediates Anti-Inflammatory Signaling via Myeloid AMPKα1 in Murine Traumatic Optic Neuropathy (TON)
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413626 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Naseem Akhter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Arizona State University, Lake Havasu City, AZ 86403, USA. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Signal Transduction, Optic Nerve Injuries, Mice, Knockout. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, United States Department of Defense, Department of Defense.
Abstract (Originalsprache)
Traumatic optic neuropathy (TON) has been regarded a vision-threatening condition caused by either ocular or blunt/penetrating head trauma, which is characterized by direct or indirect TON. Injury happens during sports, vehicle accidents and mainly in military war and combat exposure. Earlier, we have demonstrated that remote ischemic post-conditioning (RIC) therapy is protective in TON, and here we report that AMPKα1 activation is crucial. AMPKα1 is the catalytic subunit of the heterotrimeric enzyme AMPK, the master regulator of cellular energetics and metabolism. The α1 isoform predominates in immune cells including macrophages (Mφs). Myeloid-specific AMPKα1 KO mice were generated by crossing AMPKα1Flox/Flox and LysMcre to carry out the study. We induced TON in mice by using a controlled impact system. Mice (mixed sex) were randomized in six experimental groups for Sham (mock); Sham (RIC); AMPKα1F/F (TON); AMPKα1F/F (TON+RIC); AMPKα1F/F LysMCre (TON); AMPKα1F/F LysMCre (TON+RIC). RIC therapy was given every day (5–7 days following TON). Data were generated by using Western blotting (pAMPKα1, ICAM1, Brn3 and GAP43), immunofluorescence (pAMPKα1, cd11b, TMEM119 and ICAM1), flow cytometry (CD11b, F4/80, CD68, CD206, IL-10 and LY6G), ELISA (TNF-α and IL-10) and transmission electron microscopy (TEM, for demyelination and axonal degeneration), and retinal oxygenation was measured by a Unisense sensor system. First, we observed retinal morphology with funduscopic images and found TON has vascular inflammation. H&E staining data suggested that TON increased retinal inflammation and RIC attenuates retinal ganglion cell death. Immunofluorescence and Western blot data showed increased microglial activation and decreased retinal ganglion cell (RGCs) marker Brn3 and axonal regeneration marker GAP43 expression in the TON [AMPKα1F/F] vs. Sham group, but TON+RIC [AMPKα1F/F] attenuated the expression level of these markers. Interestingly, higher microglia activation was observed in the myeloid AMPKα1F/F KO group following TON, and RIC therapy did not attenuate microglial expression. Flow cytometry, ELISA and retinal tissue oxygen data revealed that RIC therapy significantly reduced the pro-inflammatory signaling markers, increased anti-inflammatory macrophage polarization and improved oxygen level in the TON+RIC [AMPKα1F/F] group; however, RIC therapy did not reduce inflammatory signaling activation in the myeloid AMPKα1 KO mice. The transmission electron microscopy (TEM) data of the optic nerve showed increased demyelination and axonal degeneration in the TON [AMPKα1F/F] group, and RIC improved the myelination process in TON [AMPKα1F/F], but RIC had no significant effect in the AMPKα1 KO mice. The myeloid AMPKα1c deletion attenuated RIC induced anti-inflammatory macrophage polarization, and that suggests a molecular link between RIC and immune activation. Overall, these data suggest that RIC therapy provided protection against inflammation and neurodegeneration via myeloid AMPKα1 activation, but the deletion of myeloid AMPKα1 is not protective in TON. Further investigation of RIC and AMPKα1 signaling is warranted in TON.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Arizona State University, Lake Havasu City, AZ 86403, USA.
- Department of Translational Neuroscience, Barrow Neurological Institute, St Joseph's Hospital and Medical Center (SJHMC), Phoenix, AZ 85013, USA.
- Department of Biotechnology, Centre for Virology, Hamdard University, New Delhi 110062, India.
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center (SJHMC), Phoenix, AZ 85013, USA.
- Department of Neurology, Henry Ford Medical Center, Detroit, MI 48202, USA.
- Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
ORCID-Profile: Laxman D Gangwani, Saif Ahmad
Förderung
- NINDS NIH HHS
- United States Department of Defense
- Department of Defense
- Barrow Neurological Foundation
- US National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)
Zitieren
APA
Akhter, N., Contreras, J., Ansari, M. A., Ducruet, A. F., Hoda, M. N., Ahmad, A. S., Gangwani, L. D., Bhatia, K., & Ahmad, S. (2024). Remote Ischemic Post-Conditioning (RIC) Mediates Anti-Inflammatory Signaling via Myeloid AMPKα1 in Murine Traumatic Optic Neuropathy (TON). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413626
Vancouver
Akhter N, Contreras J, Ansari MA, Ducruet AF, Hoda MN, Ahmad AS, et al. Remote Ischemic Post-Conditioning (RIC) Mediates Anti-Inflammatory Signaling via Myeloid AMPKα1 in Murine Traumatic Optic Neuropathy (TON). International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413626
BibTeX
@article{Akhter2024,
author = {Akhter, Naseem and Contreras, Jessica and Ansari, Mairaj A and Ducruet, Andrew F and Hoda, Md Nasrul and Ahmad, Abdullah S and Gangwani, Laxman D and Bhatia, Kanchan and Ahmad, Saif},
title = {Remote Ischemic Post-Conditioning (RIC) Mediates Anti-Inflammatory Signaling via Myeloid AMPKα1 in Murine Traumatic Optic Neuropathy (TON)},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413626}
}
EUVIMED